Pricing and patents of HIV/AIDS drugs in developing countries

This article provides empirical evidence on the impact of patents on drug prices across developing countries. It uses sales data on human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS) drugs in a sample of 34 low- and middle-income countries between 1995 and mid-2000. The main findings are that patents do shift drug prices up, drug prices are correlated to per capita income levels and drug firms follow a skimming strategy when pricing new HIV/AIDS drugs. That is, there is across country and intertemporal price discrimination in the global drug markets.     

Policy–making in the EU: the bananarama story, the WTO and policy transparency

The EU banana policy is manifestly bad. But despite a healthy policy transparency process and comprehensive public criticisms of its extreme inefficiencies, its costs have been growing progressively worse and more disruptive of international commerce. This raises serious doubts about the WTO process, and the policy transparency process itself. At the very least, the EU bananarama story told here means we should not be complacent about either.     

A SURVEY OF THE COSTS OF WORLD SUGAR POLICIES

The world sugar market has long been characterized by volatileprices and widespread intervention. Controls on domestic prices,demand, and supply have created an inefficient pattern of worldproduction, consumption, and trade. Without government controls,production would shift from the countries with higher cost,subsidized production (especially the European Community, Japan,and the United States) to the countries with lower costs (suchas Australia, Brazil, and Thailand). The resources saved couldthen be directed to other activities. Sugar policies in countries with high costs reduce world sugarprices quite substantially in the long run and increase pricevariability significantly; production controls in countrieswith low costs increase world prices somewhat and also increasetheir variability. What would happen if all interventions ceased? Average worldsugar prices would probably— but not definitely—rise. World prices would definitely vary less, and economicconditions would definitely improve, especially in developingcountries that depend heavily on sugar exports. But the prospectsfor substantial reform of the sugar market are not promising,even though the GATT Uruguay Round continues. This article putsforward some modest proposals for changing the existing interventionsto lessen economic distortions and reduce costs.      

Global economic effects of the EU Common Agricultural Policy

Among distortions in international agricultural trade, those imposed by the European Union (EU) are the most disruptive. Under the Common Agricultural Policy (CAP), the EU has switched from being a large net importer of agricultural products to a large exporter. This has greatly altered world agricultural markets, imposing substantial costs on the EU itself and efficient agricultural exporters in the rest of the world. We show how the CAP has affected world agricultural markets and present estimates of the associated costs. First we assess the aggregate costs broken down by various product categories. Next we provide a specific example of one product, sugar.     

Payoffs from research and development along the Australian food value chain: a general equilibrium analysis

The payoffs and distribution of payoffs from research and development (R&D) along the food value chain depend on many interacting economic factors. To quantify these, we have developed a general equilibrium model of the Australian economy with detailed farming, processing and marketing information. We use the model to assess potential payoffs and distributions from various R&D scenarios that lead to demand expansion and productivity improvement. We find that productivity improvement caused by R&D is unambiguously beneficial to the whole economy while the benefits of export or domestic market demand expansion mainly accrue to the primary producers and processing industry, when the economy is at full employment. Also, productivity improvement from R&D on‐farm may benefit processors while improvements postfarm may benefit farmers.     

Generic Entry into the Regulated Spanish Pharmaceutical Market

This paper empirically analyses entry by generic firms into the strictly regulated Spanish pharmaceutical market. We estimate a fixed effects negative binomial entry model using a panel of 77 active ingredient markets during the period 1999–2005. The results show that generic entry depends positively on revenues, the age of the market, and the number of previous brand-name competitors, and negatively on the number of generic incumbents. We also find that regulation may drive out competition since, contrary to what policy makers might expect, the system of reference pricing restrains generic entry.